Navigation Links
Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
Date:5/13/2009

COSTA MESA, Calif., May 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has signed a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Federal laboratories of the United States Department of Defense.

Under the agreement the company would provide information that would be used by NMRC and WRAIR for preparation, writing, and submission to the FDA of an Investigational New Drug (IND) application for the use of Oxycyte(R) for the treatment of decompression sickness. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.

For more color on what this agreement means to the company, please read today's blog by Oxygen Biotherapeutics, Inc. chairman and CEO, Chris Stern, which can be accessed via the Shareholder Forum link on the Investor Relations page of the company website at www.oxybiomed.com. It can also be accessed directly by pasting the following link into a web browser: http://eshareholderforum.com/oxbo/Chris_Stern/.

About the Walter Reed Army Institute of Research

Walter Reed Army Institute of Research is the largest, most diverse, and oldest laboratory in the US Army Medical Research and Material Command. It conducts research on a range of military relevant issues, including naturally occurring infectious diseases, combat casualty care, operational health hazards, and medical defense against biological and chemical weapons. WRAIR is the Department of Defense's lead agency for infectious disease research and a crucial source of research support for medical product development.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
2. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
3. G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab
4. Octi-Flo2™ - 8 Patient Portable Oxygen Delivery System
5. House Republican Leader Boehner Says CMS Policies on Home Oxygen Therapy Will Potentially Harm Care Available to Medicare Beneficiaries
6. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
7. Ozone/Oxygen Shot Helps Heal Herniated Disk
8. OxygenToGo Is Poised To Help Airlines Struggling With New Portable Oxygen Concentrator Regulations From The U.S. DOT
9. Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use
10. Calling Policies Unreasonable, 123 Members of Congress Press for Changes in Medicare Home Oxygen Policies for Emergency Care, Supplies and Other Obligations After 36 Months of Service
11. An atmosphere rich in CO2 and oxygen enhances the quality of refrigerated potato
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Melbourne, FLA (PRWEB) , ... February 09, 2016 ... ... the team at Clevens Face and Body Specialists are delighted to welcome a ... Certified ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/9/2016)... ... February 09, 2016 , ... Center ... who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid ... applied behavior analysis (ABA) is key to providing effective treatment for individuals with ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., ... introduction of the newly designed, innovative shoulder wrap. The newly designed shoulder ... for the injured arm and shoulder to promote faster healing. It is highly ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: ... 2015 fourth quarter and full year financial results on ... financial markets.  Company management will host a live audio ... p.m. GMT to discuss fourth quarter and full year ... update and guidance for 2016 financial results. ...
(Date:2/9/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQB: ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference which ... New York City . The Company,s presentation will ... pm by Gerald E. Commissiong , President & ...
(Date:2/9/2016)... "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: ... global market for blood monitoring & cardiac monitoring devices was valued ... US$ 24,830.1 million by 2019 at a CAGR of 6.8% from ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth of ...
Breaking Medicine Technology: